[Adriamycin versus ftorafur in the prevention of recurrence of superficial carcinoma of the bladder].
We performed a randomized prospective study in 40 patients with primary superficial carcinoma of the bladder who had been submitted to TUR. These patients were divided into two groups; one received intravesical adriamycin and the other oral ftorafur. We analyzed tumor size, number and grade and determined the recurrence rate (IR), recurrence rate/month (RR) recurrence rate/cystoscopy (RIC), disease-free interval, survival curves, and drug toxicity. After a mean follow-up of 19.7 months for the patient group that received adriamycin and 20.2 months for the group on oral ftorafur, the IR, RR, and RIC for the group on adriamycin were 40, 2.20 and 0.08%, respectively, and 33.3, 1.64 and 0.07% for the patient group on ftorafur (difference: NS). Drug toxicity was practically absent for the group on adriamycin whereas treatment had to be discontinued in two of the patients on ftorafur due to gastric intolerance. Furthermore, ftorafur was shown to cause a transient increase of transaminase levels in 4 patients, cutaneous changes and alterations in fingernails in 1 patient, and intense dermatitis during the last month of treatment in another patient. However, it was not necessary to discontinue treatment.
Unda Urzaiz
M
M
Servicio de Urología, Hospital Civil de Basurto, Bilbao, España.
Zubiaur Líbano
C
C
Pérez Fernández
A
A
Iriarte Soldevilla
J I
JI
Flores Corral
N
N
D002277:Carcinoma / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D011446:Prospective Studies; D011897:Random Allocation; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery
D005641:Tegafur; D004317:Doxorubicin
Adriamicina versus ftorafur como profilaxis de recidiva en el carcinoma vesical superficial.